Last updated 35 hours ago
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)
440 patients around the world
Available in Spain, Brazil, Argentina, United States
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
440Patients around the world
This study is for people with
Multiple myeloma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Participants must have relapsed or refractory multiple myeloma (RRMM).Participants must have received at least 1 but no greater than 3 prior multiple myeloma (MM) regimens which may include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody, and be refractory to lenalidomide (LEN) (progression on or within 60 days of completing LEN therapy).Participants must have a documented diagnosis of MM as per International Myeloma Working Group Criteria.Participants must have measurable disease during screening.Participants must have adequate organ function.Participants must have an Eastern Cooperative Oncology group performance status 0 or 1.
- Participants must not have known active or history of central nervous system (CNS) involvement of Multiple Myeloma (MM).Participants must not have solitary plasmacytomas or non-secretory myeloma without other evidence of measurable disease.Participants must not need urgent treatment due to rapidly progressing MM.Other protocol-defined Inclusion/Exclusion criteria apply.
SponsorJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
Conditions
Multiple myeloma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06615479
